The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature

• Päätekijät: Zhenpeng Wen (Tekijä), Daoli Ye (Tekijä), Qiancheng Hu (Tekijä), Hongfeng Gou (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2024-10-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Gastric cancer (GC) is a malignancy with poor prognosis and high heterogeneity. For HER2-positive, PD-L1 negative metastatic GC patients, chemotherapy plus trastuzumab is the first-line therapy. However, such patients soon acquired resistance to treatment, especially to trastuzumab during the treatm...